Pros Holdings Inc (PRO) Stock News

Dimensional Fund Advisors Ltd. has disclosed a 1.27% interest in Prologis Inc., comprising 12,058,325 USD 0.01 common shares as of September 10, 2026. The disclosure was made under Rule 8.3 of the Takeover Code, with a purchase of 841 shares at $34.41 per unit and a transfer out of 324 shares also noted during the reporting period.

Rosen Law Firm is notifying investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its sales practices, including use of undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess inventory of over 10,000 units, and made unachievable 2025 guidance. Investors with losses exceeding $100,000 are encouraged to seek counsel.

Kirby McInerney LLP is reminding PROCEPT BioRobotics investors of the September 22, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges the company made false statements about handpiece unit sales by concealing an extensive discount program that artificially inflated revenues and created over 10,000 excess units in field inventory. Stock declined significantly following earnings misses and guidance reductions in August, November 2025, and February 2026.

PROCEPT BioRobotics Corporation faces a class action securities fraud lawsuit alleging the company used an undisclosed discount program to artificially inflate handpiece sales and revenues between February 2024 and February 2026. The scheme allegedly created excess field inventory of over 10,000 units and misled investors about business performance, resulting in significant stock price declines following quarterly earnings revelations.

Ferrari N.V. has purchased 35,641 common shares across Euronext Milan and NYSE as part of its third tranche of a multi-year €3.5 billion share buyback program announced during the 2025 Capital Markets Day. As of September 4, 2026, the company has invested €523.4 million to repurchase 1,736,825 shares since January 5, 2026, representing 0.92% of total issued common shares.

Dimensional Fund Advisors Ltd. has disclosed a 1.27% interest in Prologis Inc, comprising 12,055,120 USD 0.01 common shares as of September 4, 2026. The disclosure includes recent dealings involving purchases and sales of shares at prices ranging from approximately $137.86 to $138.22 per unit. Dimensional also made disclosures regarding Segro PLC in relation to the same offer.

Rosen Law Firm alerts PROCEPT BioRobotics investors with losses exceeding $100K about a September 22, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges PROCEPT made materially false statements regarding undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory exceeding 10,000 units, and rendered 2025 guidance unachievable.

Investor rights law firm Halper Sadeh LLC is investigating GoPro's proposed sale to Starman Optical for $1.14 per share. The firm questions whether the board obtained the best price, conducted a fair sales process, and made adequate disclosures to shareholders. The investigation suggests potential conflicts of interest and insider benefits that may not be available to ordinary shareholders.

Rosen Law Firm is notifying PROCEPT BioRobotics Corporation investors of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created over 10,000 excess units of field inventory, exposing the company to material operational and financial risks.

A securities class action has been filed against PROCEPT BioRobotics for allegedly withholding information about handpiece sales practices. The company allegedly used undisclosed bulk order discount programs to artificially inflate sales by pulling forward orders from future quarters, resulting in excess customer inventory exceeding 10,000 units. The stock declined approximately 48% from August 2025 to February 2026 as the company made successive downward revisions and eventually disclosed the inventory issues.

Pomerantz Law Firm has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging securities fraud and unlawful business practices. The lawsuit stems from the company's repeated mismanagement of inventory and missed sales guidance. PROCEPT failed to disclose that handpiece sales significantly exceeded procedures, resulting in over 10,000 units of excess field inventory. The company's stock declined sharply following three earnings announcements in 2025-2026, with the most recent showing a 30% sequential decline in quarterly handpiece sales. Investors have until September 22, 2026, to request Lead Plaintiff status.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false and misleading statements regarding its business operations. The company allegedly used undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory of over 10,000 units, and failed to disclose risks that prevented it from achieving 2025 guidance. Stock prices fell significantly following earnings announcements in August, November 2025, and February 2026 that revealed lower-than-expected sales and inventory management issues.

Ferrari N.V. has completed its €250 million second tranche of share buybacks, purchasing 815,739 common shares across Euronext Milan and NYSE for €249.999 million. The company announced a third tranche of up to €250 million starting September 2, 2026, to be executed through non-discretionary agreements with primary financial institutions. Since January 2026, Ferrari has repurchased 1,701,184 shares totaling €510.76 million as part of its €3.5 billion multi-year buyback program expected to conclude by 2030.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about its business between February 2024 and February 2026. The company allegedly used an undisclosed discount program to artificially inflate handpiece sales, creating excess inventory of over 10,000 units. Stock prices fell significantly following three earnings announcements revealing lower-than-expected sales and inventory issues. Shareholders have until September 22, 2026 to file lead plaintiff motions.

UMH Properties secured a new $10.2 million Fannie Mae mortgage at 6.03% fixed rate for a 267-site community through Wells Fargo. After paying off a $2.8 million existing mortgage, the company generated $7.4 million in additional proceeds to deploy toward acquisitions, expansions, rental homes, and debt repayment. The community has been improved from 69% to 95% occupancy since acquisition in 2014.

Rosen Law Firm reminds investors of the September 22, 2026 lead plaintiff deadline in a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created excess inventory of over 10,000 units, exposing the company to material operational and financial risks.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 to February 25, 2026). The complaint claims the company misrepresented that the differential between handpiece sales and procedures remained consistent, when in fact their sales tactics pulled forward demand artificially. The deadline to serve as lead plaintiff is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for failing to disclose material inventory issues. The company revealed on February 25, 2026 that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to plummet approximately 18% in two days, from $27.84 to $22.69 per share, as quarterly handpiece sales declined nearly 30% and the company missed annual revenue guidance by tens of millions of dollars. Investors who purchased shares between February 28, 2024 and February 25, 2026 have until September 22, 2026 to file lead plaintiff applications.

Pomerantz Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for alleged securities fraud. The lawsuit stems from PROCEPT's repeated missed sales guidance, accumulation of excess field inventory exceeding 10,000 units, and significant stock price declines following earnings announcements in August 2025, November 2025, and February 2026. Investors have until September 22, 2026, to join the class action.

A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about product demand. The company allegedly used undisclosed discount programs to inflate handpiece unit sales, resulting in overstocking. PROCEPT's stock fell over 18% on February 25, 2026, when the company revealed that handpiece sales had consistently exceeded procedures. Investors have until September 22, 2026, to seek lead plaintiff status.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures. The company allegedly accumulated over 10,000 excess units in field inventory and was unable to achieve its 2025 guidance. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). The company is accused of misleading investors about U.S. handpiece sales that exceeded procedures, resulting in over 10,000 units of excess inventory that would cause significant revenue declines. Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging securities fraud. The company allegedly failed to disclose an extensive discount program that artificially inflated handpiece sales and revenues between February 2024 and February 2026. The undisclosed practices led to excess field inventory exceeding 10,000 units and significant stock price declines following quarterly earnings announcements. Shareholders who purchased PROCEPT securities during the class period have until September 22, 2026 to file a lead plaintiff motion.

Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.

Rosen Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs to artificially inflate handpiece unit sales and revenues, created excess inventory of over 10,000 units, and provided unrealistic 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is September 22, 2026.

Robbins Geller has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding undisclosed discount programs that artificially inflated sales figures and created excess field inventory. The lawsuit covers investors who purchased PRCT stock between February 28, 2024 and February 25, 2026. Multiple stock price declines followed earnings announcements revealing lower-than-expected handpiece sales and inventory management issues.

Dimensional Fund Advisors Ltd. has disclosed a 1.26% interest in Prologis Inc, comprising 11,792,280 USD 0.01 common shares as of July 31, 2026. The disclosure includes recent purchases of 4,154 shares at prices around $144.10 per share. Dimensional also made concurrent disclosures regarding Segro PLC in relation to the same offer period.

Rosen Law Firm has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The firm claims the company's 2025 guidance lacked a reasonable factual basis. Investors must move the court by September 22, 2026 to serve as lead plaintiff.